Real-Time Analyzers Develops Rapid COVID-19 Saliva Test
“The absence, to this point, of a rapid and accurate self-test has been the predominant challenge in controlling the spread of COVID-19,” said Dr. Stuart Farquharson, President, Real-Time Analyzers. “With our new saliva-based test, users can quickly and easily determine if they are infected with COVID-19, helping to prevent further spread and enabling those who test positive to make an informed decision regarding personal contact and more quickly begin the process of contact tracing. For those not infected, the test can provide a welcome measure of personal relief.”
Ideal for the workplace, schools, sport teams and events, RTA’s COVID-19 Saliva Antigen Test kit is currently entering its second stage of FDA testing. Approval is expected in November. Once approved, the kit will be available to the general public at a cost of $50 for a single kit and as low as $10 per kit for volume orders. In an effort to encourage more people to get tested, RTA will provide refunds to those who test positive.
About Real-Time Analyzers:
Real-Time Analyzers, Inc. (RTA) is a privately owned company founded in 2001. RTA develops spectroscopy-based products for chemical, biochemical, and pathogen analysis. The core employees have over 100 years combined experience in building instruments and developing analyses. RTA has delivered numerous analyzers to the US Army, Air Force, Navy and Marine Corps, for use in the Middle East. Additional RTA analyzers have been delivered to the Australian, Canadian and United Kingdom governments, and NASA. For more information, please visit www.RTA.biz.
Dr. Stuart Farquharson
Real-Time Analyzers, Inc.
Source: Real-Time Analyzers, Inc.